UCP2 and metabolic dysfunction-associated steatotic liver disease: Enhanced UCP2 expression is able to respond oxidative stress by controlling production of mitochondrial superoxide [26]; therefore, it may be a therapeutic target for management of oxidative damage and metabolic imbalance in NAFLD [25].